Akorn Stock Price, News & Analysis (NASDAQ:AKRX)

Akorn trades on the NASDAQ under the ticker symbol "AKRX."

Akorn, Inc. (NASDAQ:AKRX) announced its quarterly earnings data on Thursday, August, 1st. The company reported ($0.02) EPS for the quarter, beating the consensus estimate of ($0.11) by $0.09. The business earned $178 million during the quarter, compared to analysts' expectations of $171.97 million. Akorn had a negative net margin of 72.25% and a negative return on equity of 17.88%. The firm's revenue was down 6.8% on a year-over-year basis. View Akorn's Earnings History.

Akorn is scheduled to release their next quarterly earnings announcement on Thursday, October 31st 2019. View Earnings Estimates for Akorn.

Akorn will be holding an earnings conference call on Thursday, October 31st at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Akorn issued an update on its FY 2019 earnings guidance on Thursday, August, 1st. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $690-710 million, compared to the consensus revenue estimate of $692.99 million.

4 Wall Street analysts have issued 1-year price targets for Akorn's shares. Their forecasts range from $4.00 to $11.00. On average, they anticipate Akorn's stock price to reach $7.00 in the next year. This suggests a possible upside of 51.8% from the stock's current price. View Analyst Price Targets for Akorn.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Akorn in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Akorn.

Media stories about AKRX stock have trended somewhat positive this week, InfoTrie Sentiment Analysis reports. The research firm scores the sentiment of news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Akorn earned a daily sentiment score of 0.8 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View News Stories for Akorn.

Akorn saw a decline in short interest in September. As of September 30th, there was short interest totalling 10,920,000 shares, a decline of 13.0% from the August 30th total of 12,550,000 shares. Based on an average daily trading volume, of 1,920,000 shares, the short-interest ratio is presently 5.7 days. Currently, 11.6% of the company's shares are short sold. View Akorn's Current Options Chain.

Some companies that are related to Akorn include Biohaven Pharmaceutical (BHVN), PTC Therapeutics (PTCT), Ra Pharmaceuticals (RARX), BridgeBio Pharma (BBIO), Intercept Pharmaceuticals (ICPT), Amicus Therapeutics (FOLD), Xencor (XNCR), Ligand Pharmaceuticals (LGND), Cambrex (CBM), Zai Lab (ZLAB), Agios Pharmaceuticals (AGIO), Zogenix (ZGNX), Portola Pharmaceuticals (PTLA), Prestige Consumer Healthcare (PBH) and Apellis Pharmaceuticals (APLS).

Based on aggregate information from My MarketBeat watchlists, some companies that other Akorn investors own include Celgene (CELG), Integrated Device Technology (IDTI), Skechers USA (SKX), Rite Aid (RAD), Lannett (LCI), Bank of America (BAC), Quantenna Communications (QTNA), Ulta Beauty (ULTA), Paycom Software (PAYC) and Square (SQ).

Akorn's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Assenagon Asset Management S.A. (0.18%), State of Alaska Department of Revenue (0.06%), Nisa Investment Advisors LLC (0.03%) and CIBC Private Wealth Group LLC (0.01%). Company insiders that own Akorn stock include Alan D Weinstein, Brian Tambi, John N Kapoor, Joseph Bonaccorsi, Steven J Meyer and Terry Allison Rappuhn. View Institutional Ownership Trends for Akorn.

AKRX stock was sold by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A.. View Insider Buying and Selling for Akorn.

AKRX stock was acquired by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue, Nisa Investment Advisors LLC and CIBC Private Wealth Group LLC. Company insiders that have bought Akorn stock in the last two years include Alan D Weinstein, Joseph Bonaccorsi, Steven J Meyer and Terry Allison Rappuhn. View Insider Buying and Selling for Akorn.

Shares of AKRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of AKRX stock can currently be purchased for approximately $4.61.

Akorn has a market capitalization of $580.17 million and generates $694.02 million in revenue each year. The company earns $-401,910,000.00 in net income (profit) each year or ($0.36) on an earnings per share basis. Akorn employs 2,191 workers across the globe.View Additional Information About Akorn.

The official website for Akorn is http://www.akorn.com/.

Akorn's mailing address is 1925 WEST FIELD COURT SUITE 300, LAKE FOREST IL, 60045. The company can be reached via phone at 847-279-6100 or via email at [email protected]